上海复宏汉霖生物技术股份有限公司 Henlius
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Henlius' Serplulimab (anti-PD-1 mAb) Granted Breakthrough Therapy Designation by China NMPA for Neo-/Adjuvant Treatment for Gastric Cancer 2025-11-20 18:52
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US 2025-11-17 22:06
Phase 3 Clinical Trial of HANSIZHUANG Plus Chemotherapy Meets Primary Endpoint in Neoadjuvant/Adjuvant Gastric Cancer, Greenlighting Early NDA Submission 2025-10-09 20:50
European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively 2025-09-19 19:59
FUTUONING Sets Sail Commercially with First Prescriptions Across China 2025-09-05 18:12
US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively 2025-09-02 21:10
Henlius Keeps Steady Growth in H1 2025: Overseas Product Profits Soar 200%+, Innovation Fuels Global Reach 2025-08-25 21:18
Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar 2025-04-29 23:39
Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar 2025-04-29 23:38
Henlius 2025 Global R&D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights 2025-04-17 16:07
Henlius 2025 Global R&D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights 2025-04-16 23:30
Putting Patients First, Co-Creating a Bright Future for Human Health: Henlius Releases 2024 ESG Report 2025-04-16 23:22
Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY 2025-03-24 23:09
Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY 2025-03-24 22:54
Henlius Receives Orphan Drug Designation for Innovative Anti-HER2 mAb HLX22 in the U.S. for Gastric Cancer 2025-03-19 23:17
Henlius Receives Orphan Drug Designation for Innovative Anti-HER2 mAb HLX22 in the U.S. for Gastric Cancer 2025-03-19 21:00
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S. 2025-02-06 19:40
Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) 2025-02-05 22:05
Henlius and SVAX Forge Strategic Partnership in the MENAT Market 2024-11-09 00:35
Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer 2024-09-21 13:42
1 2 3 4